Expression of sex steroid receptor subtypes in normal and malignant breast tissue - A pilot study in postmenopausal women

Acta Oncologica

Volumn 45, Issue 1, 2006, Pages 54-60

  Lofgren L ^a   Sahlin, L ^b   Von Schoultz, B ^b   Fernstad, R ^a   Skoog, L ^b   Von Schoultz, E ^b  

^a ST GÖRAN S HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR; RECEPTOR SUBTYPE; SEX HORMONE; STEROID RECEPTOR;

ARTICLE; BREAST; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PILOT PROJECTS; POSTMENOPAUSE; RECEPTORS, PROGESTERONE;

EID: 32244441859     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500371865     Document Type: Article

References (29)

1. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci 1996;93:5925-30.
2. Gustafsson JA, Warner M. Estrogen receptor beta in the breast, role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol 2000;74:245-8.
3. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001;61:2537-41.
4. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-78.
5. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 1998;58:3197-201.
6. Conneely OM, Lydon JP, De Mayo F, O'Malley BW. Reproductive functions of the progesterone receptor. J Soc Gynecol Investig 2000;7:S25-32.
7. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004;10:2751-60.
8. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women, the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
9. Santen RJ. Risk of breast cancer with progestins, critical assessment of current data. Steroids 2003;68:953-64.
10. Isaksson E, Wang H, Sahlin L, von Schoultz B, Cline JM, von Schoultz E. Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A and B in breast tissue from surgically postmenopausal cynomolgus macaques. Breast Cancer Res Treat 2003;79:233-9.
11. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer, a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-68.
12. Cheng G, Li Y, Omoto Y, Wang Y, Berg T, Nord M, et al. Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland. J Clin Endocrinol Metab 2005;90:435-44.
13. Löfgren L, Skoog L, von Schoultz E, Tani E, Isaksson E, Fernstad R, et al. Hormone receptor status in breast cancer - a comparison between surgical specimens and fine needle aspiration biopsies. Cytopathology 2003;14:136-42.
14. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
15. Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL, Walker RA. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J Pathol 2002;198:450-7.
16. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003;201:213-20.
17. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004;11:537-51.
18. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy, physiological complexity belies therapeutic simplicity. Science 2004;304:1269-73.
19. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001;276:36869-72.
20. Cowley SM, Parker MG. A comparison of transcriptional activation by ER alpha and ER beta. J Steroid Biochem Mol Biol 1999;69:165-75.
21. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997;277:1508-10.
22. Cunha GR, Young P, Hom YK, Cooke PS, Taylor JA, Lubahn DB. Elucidation of a role for stromal steroid hormone receptors in mammary gland growth and development using tissue recombinants. J Mammary Gland Biol Neoplasia 1997;2:393-402.
23. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002;277:5209-18.
24. Shyamala G, Yang X, Cardiff RD, Dale E. Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci 2000;97:3044-9.
25. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy, the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
26. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, et al. Adaptive hypersensitivity to estrogen, mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr Relat Cancer 2003;10:111-30.
27. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000;156:29-35.
28. Myers E, Fleming FJ, Crotty TB, Kelly G, McDermott EW, O'Higgins NJ, et al. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer 2004;91:1687-93.
29. Omoto Y, Inoue S, Ogawa S. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 2001;163:207-12.